To hear about similar clinical trials, please enter your email below
Trial Title:
An Investigation Into Dielectric Assessment of Permittivity and Conductivity in Human Using a Novel Electrical Capacitance Tomography Scanner
NCT ID:
NCT06264934
Condition:
Breast Cancer
Benign Breast Disease
Conditions: Official terms:
Breast Diseases
Fibrocystic Breast Disease
Conditions: Keywords:
Breast Cancer
Electrical Capacitance Tomography
Permittivity
Study type:
Observational
Overall status:
Recruiting
Study design:
Time perspective:
Prospective
Intervention:
Intervention type:
Device
Intervention name:
Breast scan using the Z-scanner
Description:
Four repeated scans of both breasts using the Z-scanner.
Arm group label:
Part A
Intervention type:
Device
Intervention name:
Breast scan using the Z-scanner
Description:
A scan of both breasts using the Z-scanner.
Arm group label:
Part B
Summary:
The goal of this observational study is to investigate the ability of a the Z-scanner to
identify and differentiate cancer and benign lesions from healthy breast tissue based on
permittivity. The main questions it aims to answer are:
1. Determine the permittivity values of the Z-scanner associated with healthy, benign,
and malignant tissue in human breasts.
2. Determine the repeatability, reproducibility, inter-and intra-operator variability
of the Z-scanner.
Detailed description:
Permittivity is the measure of a material's ability to store electrical energy in the
electric field. Different materials are known to have different permittivity including
the human body. Research is looking into utilising permittivity differences in the human
body to detect cancer. There is a particular focus in breast cancer because it is the
most common type of cancer in women globally, and research has shown that permittivity of
healthy breast tissue is different to cancer tissue. Furthermore, breast tissue can be
easily accessible by non-invasive means and has well-established tools available to
support cancer detection. However, results from many studies vary greatly and more
research is needed to understand how permittivity can be used in cancer research. Zedsen
Limited has developed a permittivity measuring device (Z-scanner) capable of measuring a
material's permittivity. The purpose of this study is to establish the permittivity of
healthy, benign, and cancer tissue associated with the Z-scanner.
90 women attending a routine screening assessment clinic or a one stop clinic at Charing
Cross Hospital will be recruited over the course of a year. The study is split into 2
parts. Part A will recruit 20 participants to assess whether scanner results can be
repeated and reproduced by different users and hardware. Part B will recruit 70
participants to assess whether the Z-scanner can differentiate between benign and
cancerous lesion. All participants will have both their breasts scanned using the
Z-scanner during their routine appointment. This allows us to investigate the ability of
the Z-scanner to identify and differentiate benign and cancerous lesions from healthy
breast tissue based on permittivity. Results from this study can further our
understanding on how permittivity and such devices can be used in cancer research.
Criteria for eligibility:
Study pop:
20 healthy participants 35 participants with benign lesions 35 participants with
malignant lesions
Sampling method:
Non-Probability Sample
Criteria:
Inclusion Criteria:
- Attending a symptomatic clinic or other appointment at a participating breast clinic
site
- Assigned female sex at time of birth
- Aged 18 years or older at time of scan
- Willing, able and mentally competent to read, understand, and provided informed
consent in English
Exclusion Criteria:
- Participants who have undergone biopsy less than 14 days before the Z-scanner scan
- Participants with implanted electronics
- Participants with breast implants
- Participants with nipple piercings (unless they are removed prior to the scan)
- Participants who are lactating
- Pregnant participants by verbal confirmation
- Participants with pacemakers
- Participants with open breast wound
- Participants who had previous breast surgery (mastectomy, lumpectomy)
Gender:
Female
Minimum age:
18 Years
Maximum age:
N/A
Healthy volunteers:
Accepts Healthy Volunteers
Locations:
Facility:
Name:
Imperial College Healthcare NHS Trust
Address:
City:
London
Country:
United Kingdom
Status:
Recruiting
Contact:
Last name:
Lesley Honeyfield
Investigator:
Last name:
Adrian Lim
Email:
Principal Investigator
Investigator:
Last name:
Deborah Cunningham
Email:
Sub-Investigator
Investigator:
Last name:
Sylvie Flais
Email:
Sub-Investigator
Start date:
January 25, 2024
Completion date:
December 2024
Lead sponsor:
Agency:
Zedsen Limited
Agency class:
Industry
Collaborator:
Agency:
Imperial College Healthcare NHS Trust
Agency class:
Other
Source:
Zedsen Limited
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT06264934